NCT06200376View on ClinicalTrials.gov

A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Malignant Ascites

Interventions

DRUG

T3011

T3011 will be administered intraperitoneally twice a week.

Trial Locations (1)

Unknown

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors

lead

West China Hospital

OTHER